Hence, there is a strong indication of synergy between SB939 and IM in significantly reducing the viability of the primary CML progenitors with the BIM deletion polymorphism. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.